Celebrex for juvenile RA panel review
Executive Summary
Pfizer's COX-2 inhibitor Celebrex (celecoxib) for the treatment of juvenile rheumatoid arthritis in patients two years of age and older will be discussed by FDA's Arthritis Advisory Committee Nov. 29. The committee overwhelmingly supported continued marketing of Celebrex during a much publicized 2005 joint meeting with the Drug Safety & Risk Management Advisory Committee on the COX-2 inhibitor class (1"The Pink Sheet" March 7, 2005, p. 21). The November meeting will be held at the Hilton in Gaithersburg, Md. from 8 a.m. to 5 p.m....